Tonix Pharmaceuticals (NASDAQ: TNXP) Chief Medical Officer plans August 2026 retirement
Rhea-AI Filing Summary
Tonix Pharmaceuticals Holding Corp. reports an upcoming leadership change. On July 20, 2026, Dr. Gregory M. Sullivan informed the company that he will retire from his role as Chief Medical Officer, effective August 20, 2026. This reflects a planned transition in a key executive position.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Retirement notice date: July 20, 2026
CMO retirement effective date: August 20, 2026
Commission File Number: 001-36019
+1 more
4 metrics
Retirement notice date
July 20, 2026
Date Dr. Gregory M. Sullivan informed the company of his retirement
CMO retirement effective date
August 20, 2026
Effective date of Dr. Sullivan’s retirement as Chief Medical Officer
Commission File Number
001-36019
SEC Commission File Number for Tonix Pharmaceuticals Holding Corp.
IRS Employer Identification Number
26-1434750
IRS Employer Identification Number for Tonix Pharmaceuticals Holding Corp.
Key Terms
Chief Medical Officer, emerging growth company, Exchange Act
3 terms
Chief Medical Officer medical
"he will retire from his role as Chief Medical Officer of the Company"
A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.
emerging growth company financial
"Emerging growth company Item 5.02 Departure of Directors or Certain Officers"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Exchange Act regulatory
"Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter)"
A federal law that sets rules for trading securities on public exchanges, requiring companies and market participants to register, disclose regular financial information, and follow standards that promote honest, orderly markets. For investors, it matters because it creates transparency and legal protections—like stopping insider trading and ensuring timely company disclosures—so you can evaluate risks and rely on consistent rules much as players rely on a referee to keep a game fair.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What executive change did Tonix Pharmaceuticals (TNXP) disclose?
Tonix Pharmaceuticals disclosed that Dr. Gregory M. Sullivan will retire as Chief Medical Officer, effective August 20, 2026, following his formal notice to the company on July 20, 2026, as reported in a current report on Form 8-K.
When will Tonix Pharmaceuticals' (TNXP) Chief Medical Officer retire?
The Chief Medical Officer, Dr. Gregory M. Sullivan, will retire effective August 20, 2026. He notified Tonix Pharmaceuticals of his decision on July 20, 2026, providing about one month’s lead time for the transition in this key role.
Who is the Tonix Pharmaceuticals (TNXP) executive retiring from the company?
The executive retiring is Dr. Gregory M. Sullivan, who serves as Chief Medical Officer. He informed Tonix Pharmaceuticals of his planned retirement on July 20, 2026, with an effective retirement date of August 20, 2026.
What SEC form did Tonix Pharmaceuticals (TNXP) use to report the CMO retirement?
Tonix Pharmaceuticals reported the retirement of its Chief Medical Officer on a Form 8-K under the item covering departures of certain officers, elections of directors, appointments of certain officers, and related compensatory arrangements.
On what date did TNXP receive notice of its CMO’s planned retirement?
Tonix Pharmaceuticals received notice of the planned retirement of its Chief Medical Officer, Dr. Gregory M. Sullivan, on July 20, 2026. The retirement will become effective one month later, on August 20, 2026.